CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2018 State of the Science Summit on Gastrointestinal Cancers
Oncology Conference Multimedia
View more videos >>
Dr. Collisson on the Difficulty of Diagnosing Cholangiocarcinoma
Dr. Oberstein on PEGPH20 in Patients With Pancreatic Cancer
Dr. Welling on SIRT in Patients With Hepatobiliary Neoplasms
Oncology Conference Articles
Amid Success, Immunotherapy Faces Challenges in GI Malignancies
Gregory L. Beatty, MD, PhD, shares his insight on the challenges with sequencing immunotherapies in light of recent advancements in gastrointestinal malignancies.
Surgery Remains Vital in Hepatobiliary Neoplasms
Theodore H. Welling, MD, discusses the expanding role of surgery in hepatobiliary neoplasms.
Optimizing Application of Genomic Analyses Critical to Advancing Pancreatic Cancer Care
Diane M. Simeone, MD, discusses the molecular complexities of pancreatic cancer, some of the commonly identified mutations, and ongoing clinical trial efforts that may be game changing for the field.
Collisson Covers Cholangiocarcinoma and Colon Cancer Challenges
Eric A. Collisson, MD, speaks to the challenges and emerging advancements in cholangiocarcinoma and colon cancer.
Expert Calls for Smarter Clinical Trials in Pancreatic Neoplasms
Paul E. Oberstein, MD, discusses incorporating novel agents and sequencing approaches in advanced pancreatic neoplasms.
Dr. Beatty on the Potential for Immunotherapy in GI Malignancies
Gregory L. Beatty, MD, PhD, assistant professor of medicine, director of Tanslation Research, Pancreatic Cancer Research Center, University of Pennsylvania Perelman School of Medicine, discusses the potential for immunotherapy in gastrointestinal malignancies.
OncLive News Network On Location: In San Diego Monday, December 3
CDK4/6 Inhibitors Are Transforming Treatment in HR+ Breast Cancer
Paradigm Evolving in HER2+ Breast Cancer With CNS Mets
BiTE Antibodies Show Encouraging Activity in Myeloma, AML
Acalabrutinib Achieves High Response Rates in CLL
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.